Citations

Clear

9383 citation(s) found for "Thomas, PS".

PART characterization using MK‐6240 and Flortaucipir
Soares, Carolina, Ferreira, Pamela C.L., Madeiros, Marina Scop, Rocha, Andreia, Bellaver, Bruna, Oliveira, Markley Silva , Povala, Guilherme, Amaral, Lívia , Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Soares, Carolina , Ruppert, Emma Patrice , Ferreira, Pâmela C.L. , Madeiros, Marina Scop, Rocha, Andreia, Rodrigues, Matheus Scarpatto , Bellaver, Bruna , Povala, Guilherme , Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106723 Get It

Abstract Background Older adults with brain tau pathology but no evident amyloid‐beta (A) pathology can be referred to as primary age‐related tauopathy (PART). However, in vivo characterization of PART using biomarkers remains unclear, varying based on the method used to define tau pathology (e.g. different tau‐PET tracers). Here, we conducted a head‐to‐head characterization of PART using two different tau‐PET tracers. Method We studied 433 individuals from the HEAD cohort (244 CU, 138 MCI, and 51 with dementia). Participants underwent clinical assessments, MRI, A‐PET, both MK‐6240 and Flortaucipir scans, and a subset with plasma biomarkers ( n = 332). A‐PET positivity was defined as Centiloid>24. Tau‐positivity(T) was determined by MK‐6240 and Flortaucipir SUVR values exceeding the mean+2SD in at least one Braak region anchored in CU A‐ individuals followed by visual confirmation in A‐/T+ cases. Concordance across biomarkers was assessed among PART (A‐/T+), A‐/T‐ and A+/T+ groups. Plasma GFAP, p ‐tau217, NFL levels, and Centiloids were compared across A/T groups using linear regression. Result We found a total of 25 (5.8 %) cases classified as A‐/T+ defined by at least one tau tracer (74±6.3 years, 52% females, 17 CU, 3 MCI, 5 with dementia). Detection of A‐/T+ cases varied by tracer: MK‐6240( n = 20), Flortaucipir( n = 16) (Figure 1A). Among A‐/T+ individuals, MK‐6240 identified 13 CU, 4 MCI, and 3 dementia cases, while Flortaucipir identified 11 CU, 3 MCI, and 2 dementia cases(Figure 1B). Concordance between MK‐6240 and Flortaucipir in A‐/T+ cases was low ( n = 11, 44%)(Figure 1C). A‐/T+ individuals showed no significant biomarker differences from A‐/T‐ but had lower biomarker levels than A+/T+: Centiloids (MK‐6240: T=15.08, p <0.001; Flortaucipir: T=14.36, p <0.001), GFAP (MK‐6240: T=5.04, p < 0.01; Flortaucipir: T=2.92, p <0.001), p ‐tau217 (MK‐6240: T=7.77, p <0.001; Flortaucipir: T=6.34, p <0.001), except for NFL (MK‐6240: T=1.35, p = 0.18; Flortaucipir: T=1.14, p = 0.25)(Figure 2). Representative A and tau biomarker cases (Figure 3A), along with discordant cases classified as T+ by only one tracer (Figure 3B), are illustrated. Conclusion Our preliminary analysis revealed a higher prevalence of A‐/T+ cases with MK‐6240 than Flortaucipir, low concordance between tracers and consistently lower biomarker levels in A‐/T+ compared to A+/T+. Larger studies and longitudinal analyses are necessary to ascertain the pathological trajectories of A‐/T+ individuals with varying tau biomarker profiles.
Head‐to‐Head evaluation of plasma p ‐tau217 associations with MK6240, Flortaucipir, PI2620, and RO948 tau PET tracers
Ferreira, Pamela C.L., Chan, Tevy , Bellaver, Bruna, Povala, Guilherme, Soares, Carolina, Felix, Cynthia, Rocha, Andreia, Madeiros, Marina Scop, Amaral, Lívia , Cehula, Juli, Masdeu, Joseph C., Tudorascu, Dana L, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Medeiros, Marina Scop , Ferreira, Pâmela C.L. , Bellaver, Bruna , Povala, Guilherme , Bauer‐Negrini, Guilherme , Ruppert, Emma Patrice , Soares, Carolina , Felix, Cynthia , Rocha, Andreia, Madeiros, Marina Scop, Cehula, Juli, Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106115 Get It

Abstract Background Tau phosphorylation and aggregation are hallmark features of Alzheimer's disease pathology(AD). Previous studies have shown that plasma phosphorylated tau( p ‐tau) at threonine 217 can detect AD‐related tau tangle pathology. However, the head‐to‐head association between p ‐tau217 and different tau PET tracers remains unexplored. Here, we conducted a head‐to‐head comparison of the association between plasma p ‐tau217 and four distinct tau PET tracers[MK6240, Flortaucipir(FTP), PI2620, RO948]. Method We studied 338 individuals across the AD continuum from the HEAD study[190 cognitively unimpaired elderly(CU), 109 with mild cognitive impairment(MCI), and 39 with dementia] with available FTP, MK6240, and plasma p ‐tau217 measured by ALZpath assay. A subset of 64 individuals(28 CU, 25 MCI, and 11 dementia) also had PI2620 and RO948, and p ‐tau217 measured by Lumipulse. The strength of the association was determined using t‐value maps from regression models testing the association between each tau PET tracer and plasma p ‐tau217, and the extent was measured by the percentage of significant voxels(t‐value>3.2). R‐square metric was used to determine how much of the variance in tau PET tracer estimates was explained by plasma p ‐tau217 concentrations. Associations between p ‐tau217 with tau PET were evaluated using the Spearman test. Result We found that in CU, both the extent and magnitude of the association with plasma p ‐tau217 were higher for MK6240 compared to FTP (Figure 1A‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240 than in FTP (Figure 1E‐F). In CI, the extent and magnitude of the association were similar for MK6240 and FTP. Additionally, plasma p ‐tau217 explained a similar proportion of the variance in MK6240 and FTP. Using the subset of individuals who had all tau tracers, MK6240 showed a slightly higher extent of association with p ‐tau217, followed by FTP, PI2620, and RO948 (Figure 2A‐B). The magnitude of association was stronger for MK6240, followed by PI2620, RO948, and FTP (Figure 2C‐D). Plasma p ‐tau217 explained a greater proportion of the variance in MK6240, followed by FTP, RO948, and PI2620 (Figure 2E‐F). We compared the associations between different p ‐tau217 assays, and both assays presented similar associations with all tau PET tracers (Figure 3). Conclusion In summary, our results indicate that the four tau PET tracers exhibit robust associations with plasma p ‐tau217 in similar topographical regions.
COMPREHENSIVE GENETIC INVESTIGATION REVEALS HETEROGENEOUS PATHWAYS TO OBSTRUCTIVE SLEEP APNEA
Justice, Anne E. , Pahl, Matthew C. , Gupta, Shreyash , Kim, Soriul , Thorleifsson, Gudmar, Gutierrez, Alejandro , Oliveira, Fernando Andrade de , Ackert‐Bicknell, Cheryl L. , Benediktsdottir, Bryndis, Boero, Jaime, Borthwick, Kenneth M., Chen, N., Cistulli, Peter A. , Favazzo, Lacey J. , Gottlieb, Daniel J. , Hakonarson, H., Kirchner, H. Lester , Mazzotti, Diego R, Mentch, Frank , Morgentheler, Timothy I, Penzel, Thomas, Pippin, James A. , Rasmussen-Torvik, Laura J, Shin, Chol, Singh, Bhajan, Sofer, T., Villani, David A. , Wells, Andrew D, Zee, Phyllis, Jonsdottir, Ingileif, Gislason, Thorarinn, Robishaw, Janet, Stefansson, K., Grant, Struan FA., Pack, A., Þorleifsson, Guðmar , Kim, Soriul , Thorleifsson, Gudmar , Manduchi, Elisabetta , Gutierrez, Alejandro , Cistulli, Peter A , Gottlieb, Daniel J , Magalang, Ulysses J , Mazzotti, Diego R , Mentch, Frank D , Morgenthaler, Timothy I , Rasmussen-Torvik, Laura J , Shin, Chol , Singh, Bhajan , Sofer, Tamar , Williams, Marc S , Zuscik, Michael J , Jonsdottir, Ingileif , Gislason, Thorarinn , Stefánsson, Kári , Keenan, Brendan T , Chittoor, Geetha , Hoskens, Hanne , Josyula, Navya Shilpa , Oliveira, Fernando Andrade, Malow, Beth A. , McArdle, Nigel , Morgenthaler, Timothy I. , Penzel, Thomas , Sofer, Tamar , Veatch, Olivia J. , Robishaw, Janet D. , Stefánsson, Kāri , Grant, Struan F.A. , Hallgrímsson, Benedikt , Pack, Allan I

Mayo Clinic

No container title available | January 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.08.26343696 | PMID 41542692 Get It

ABSTRACT Obstructive sleep apnea (OSA) is a common, heritable disorder with diverse clinical presentations and etiologies. We conducted a genome-wide association meta-analysis of 492,107 individuals, including 46,028 OSA cases, identifying 14 genome-wide significant loci, eight of which are novel. Analyses adjusting for body mass index (BMI) revealed three loci independent of obesity, implicating alternative biological pathways contributing to disease. Integrative functional analyses, including chromatin interaction mapping, fine-mapping, and eQTL colocalization, prioritized candidate effector genes. Notably, implicated genes in chondrocytes were associated with craniofacial morphology in both mouse and human multivariate genotype-phenotype mapping, supporting a role for craniofacial structure in OSA risk. These findings highlight key genetic pathways (obesity-related, neurological, and craniofacial) underlying the development of OSA, offering new insights into its complex etiology.
Aβ‐dependent trajectories of Braak stages for MK6240 and Flortaucipir tau PET
Bellaver, Bruna, Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Rocha, Andreia, Masdeu, Joseph C. , Tudorascu, DL, Karikari, Thomas K, Soleimani‐Meigooni, David N., Fortea, Juan M., Lowe, VJ, Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Pascoal, Tharick A, Pascual, Belén , Rocha, Andréia Silva da , Pascual, Belen , Bellaver, Bruna , Povala, Guilherme , Ferreira, Pâmela C.L. , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Rocha, Andreia, Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107040 Get It

Abstract Background Tau accumulation in the brain is postulated to follow a hierarchical pattern, known as Braak staging, originally defined in postmortem brains. PET‐based Braak stages have since been proposed, however, tau PET tracers exhibit distinct binding characteristics that might influence the detectable trajectories of tau accumulation and its relationship with other biomarkers across the AD continuum. In a head‐to‐head study, we investigated the emergence of tau positivity in each Braak region, along with plasma p ‐tau217 and GFAP, as a function of Aβ PET deposition. Method We evaluated 352 individuals from the HEAD study (205 cognitively unimpaired and 147 cognitively impaired) with head‐to‐head Aβ PET, MK6240 and Flortaucipir tau PET, and plasma p ‐tau217 (ALZpath) and GFAP (Quanterix) measures. Tau PET Braak regions, plasma p ‐tau217 and GFAP trajectories were modeled as functions of Aβ burden (Centiloid scale) using the Lowess method. Biomarkers were z‐scored anchored on young individuals ( n = 19, <28 years old). Positivity for plasma biomarkers and for each Braak region was determined when values surpassed 2.5 z‐score from the mean. Result Among the tested markers, plasma GFAP was the earliest to show abnormality as a function of Centiloid, occurring at 11 Centiloids. For MK6240, Braak I was the first regions to became positive (at 22 Centiloids), followed by Braak II (at 32 Centiloids), Braak IV (at 42 Centiloids), Braak III (at 52 Centiloids), Braak V (at 70 Centiloids) and Braak VI (at 123 Centiloid; Figure 1A). For Flortaucipir the first region to became positive was Braak IV (at 50 Centiloids), followed by Braak I and II (both at 56 Centiloids), Braak III (at 85 Centiloids) and Braak V (at 92 Centiloids). Braak VI region did not reach the threshold for positivity in our population (Figure 1B). Plasma p ‐tau217 reached the positivity threshold at 38 Centiloids. Conclusion MK6240 follows a Braak stage‐like pattern of abnormality as a function of Aβ burden, whereas for Flortaucipir, Braak IV is the first region to became abnormal. MK6240 becomes abnormal at lower Aβ burden levels compared to plasma p ‐tau217 and Flortaucipir but after plasma GFAP. Our findings suggest that MK6240 might detect tau pathology in earlier disease stages than Flortaucipir.
Impact of Neoadjuvant Induction Chemotherapy Prior to Chemoradiation on Survival and Surgical Outcomes in Real-World Esophageal Adenocarcinoma Cohort
Matoska, Thomas, Memon, Abdullah , Moreno, Lou-Anne Acevedo, Bulacan, Calista, Rein, Lisa, Banerjee, A., George, Ben, Jurkowski, Lauren , Phan, Alexandria T. , Johnstone, C. , Shukla, Monica , Gore, Elizabeth , Linsky, Paul L., Gasparri, Mario, Puckett, Lindsay L., Puckett, Lindsay , Memon, Abdullah A , Acevedo Moreno, Lou-Anne , Banerjee, Anjishnu , Phan, Alexandria , Shukla, Monica E , Puckett, Lindsay L , Rein, Lisa , Banerjee, Anjishnu , George, Ben , Johnstone, Candice, Hunt, Mallory L.

Mayo Clinic

Cancers | January 9, 2026 | Volume: 18 | Issue: 2 | Pages: 213

10.3390/cancers18020213 | PMID 41595134 Get It

Background/objectives: Improvements in esophageal adenocarcinoma (EAC) treatment have reduced mortality. While chemoradiation before surgery was previously a standard of care, updated guidelines recommend peri-operative chemotherapy without chemoradiation. Continued investigation into optimal non-operative treatment paradigms for patients who defer surgery or are not candidates for surgery and certain chemotherapy regimens is needed. The impact of induction chemotherapy prior to chemoradiation on survival and surgical outcomes remains unclear. This study assessed survival and surgical outcomes in a real-world cohort of EAC patients receiving induction chemotherapy before chemoradiation. Methods: This single-institution, IRB-approved, retrospective cohort study included patients with newly diagnosed stage II-IVb (oligometastatic for IVb) EAC who received definitive chemoradiation (radiation ≥ 40 Gy and two cycles of chemotherapy) +/− esophagectomy from 2007 to 2022. Patients receiving induction chemotherapy were compared to those who did not. Endpoints included survival and surgical outcomes. Results: A total of 141 EAC patients received definitive chemoradiation; 83 received induction chemotherapy before chemoradiation. Patients receiving induction chemotherapy were younger (p < 0.01) with slightly lower performance status (p = 0.27) and presented at a more advanced stage (p < 0.001). Median OS was 3.5 years in the induction chemotherapy group compared to 2.2 years (p = 0.10). There was no difference in pathologic complete response (p = 0.81), esophagectomy frequency (p = 0.87), or surgical downstaging between treatment groups (p = 0.84). Conclusions: In this real-world, single-institutional patient cohort investigating induction chemotherapy prior to chemoradiation in EAC, patients receiving induction chemotherapy did well but did not have a statistically significant improvement in survival outcomes or surgical outcomes. This study showed that significant numbers of real-world patients may not receive esophagectomy. Thus, prospective, randomized clinical trials are warranted to better delineate the efficacy and selection of patients for induction chemotherapy when non-operative approaches are favored.
Plasma Alzheimer's Disease Biomarker Associations with eGFR in Black and White Older Adults
Sullivan, Kevin, Blackshear, Chad , Knopman, David S., Syrjanen, Jeremy A. , Vassilaki, Maria , Jack, Clifford R., Petersen, Ronald, Windham, Gwen Gwen, Mosley, Thomas H., Griswold, Michael E., Bornhorst, Joshua , Knopman, David S. , Figdore, Daniel J. , Jack, Clifford R. , Petersen, Ronald, Mosley, Thomas H. , Algeciras‐Schimnich, Alicia , Griswold, Michael

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107141 Get It

Abstract Background Decreased kidney function, indicated by a lower estimated glomerular filtration rate (eGFR), may affect interpretation of Alzheimer's disease (AD) blood biomarkers, including phosphorylated tau ( p ‐tau) and amyloid‐beta (Aβ) peptides, due to altered clearance. However, there is limited data available to determine the influence of eGFR on these biomarkers and whether it differs by biomarker or assay type, especially in racially diverse studies of community‐based older adults. Methods We used data from 557 participants in the Mayo Clinic Study of Aging (Rochester, MN n = 182; age 79±8 years; 36.3% Female, White participants) and the UMMC MIND Center‐Mayo Clinic Study of Aging (Jackson, MS n = 375; age 69±8 years; 73% Female 27% Black participants). eGFR was determined using the 2021 CKD‐EPI Creatinine equation. Plasma biomarkers were measured using the Lumipulse immunoassays for p ‐tau217, Aβ42, and Aβ40 (Fujirebio Diagnostics; n = 420); or the mass spectrometry‐based PrecivityAD2 assay (C2N Diagnostics; n = 253) for p ‐tau217, np‐tau217, Aβ42, and Aβ40. Common ratio values were calculated. Aβ42/40 measures were inverted so higher values are worse for all biomarkers. Log base‐2 transformed regression analysis related eGFR to each single analyte and ratio; coefficients (95% CI) reflect estimated doubling in biomarker per doubling in eGFR. Group specific [MN White ( n = 182), MS White ( n = 224), MS Black ( n = 151) participants] estimates are reported, as the distribution of social determinants of health can vary across populations and locations. Results Lower eGFR was associated with higher (worse) AD‐plasma biomarkers, and group stratified estimates were mostly consistent (Figure 1). Ratios of biomarkers diminished but did not entirely alleviate associations with eGFR. For example, MN White participants’ C2N p ‐tau217 association of ‐1.47 (‐1.94, ‐1.00), was attenuated to ‐0.67 (‐1.11, ‐0.22), when using p ‐tau217/np‐tau217. Conclusions Kidney function may be associated with AD‐plasma biomarker values, even with common ratio corrections. There was not strong evidence for highly differential associations of eGFR by race/site categories, though sample sizes are currently limited. The implications for diagnosis and risk classification need to be explored further to support health equity. Optimal consideration of comorbidities on blood biomarker concentrations must continue to be informed by investigation in large, racially and ethnically diverse, community‐based studies.
2025 International Consensus Meeting on Musculoskeletal Infection: Summary From the Biofilm Workgroup on Biofilm Formation, Persistence, and Host‐Environment Interactions
Muthukrishnan, Gowrishankar , Coraça‐Huber, Débora C., Abbaszadeh, Ahmad , Abedi, Armita A., Abuhussein, Ezzuddin , Bingham, Joshua S. , Cichos, Kyle H. , Drago, L., Hamilton, John , Hickok, Noreen J., Iannotti, Ferdinando , Jensen, Louise Kruse, Li, Bingyun , Manzary, Mojieb, Moriarty, T. Fintan, McDonald, Katya , Nishitani, K., Norton, Nicholas, Oral, Ebru, Parvizi, Javad M., Raafat, Dina, Saeed, Kordo B. A., Sallai, Imre , Em, Schwarz, Siverino, Claudia , Tate, J.C. , Trobos, Margarita , Tubbs, Andie R., Hamilton, John L. , Saeed, Kordo , Abedi, Armita Armina , Bingham, Joshua S , Drago, Lorenzo , Hickok, Noreen J , Iannotti, Ferdinando , Moriarty, T Fintan , McDonald, Katya , Schwarz, Edward M , Abedi, Armita Armina , Coraça-Huber, Débora Cristina , Atkins, Gerald J. , Coenye, Tom , Jennings, Jessica Amber , Jensen, Louise Kruse , Nishitani, Kohei, Norton, Nicholas , Oral, Ebru , Parvizi, Javad , Raafat, Dina , Sekar, Amita

Mayo Clinic

Journal of Orthopaedic Research | January 9, 2026 | Volume: 44 | Issue: 1 | Pages: No page available

10.1002/jor.70130 | PMID 41506787 Get It

ABSTRACT Musculoskeletal infection (MSKI) remains a major problem after trauma and elective orthopedic surgery. Chronic MSKI is related to the formation of biofilm, which impairs diagnosis and effective treatments. Therefore, to understand and communicate global standards and best practices, the 2025 International Consensus Meeting (ICM) on MSKI created a Biofilm Section to address crucial aspects of biofilm biology pertaining to its mechanisms of drug resistance and immune evasion, and potential approaches to overcome them. This featured a 2‐year process, with final voting and discussion on May 8–10, 2025, in Istanbul, Turkey. This Consensus Article is the effort of the Biofilm Basic Mechanisms Workgroup, which interpreted the results on ICM questions related to (1) the infectious microenvironment; (2) appropriate inocula in preclinical research; (3) biofilm behavior in infected tissues; and (4) synergy within biofilms and with other comorbidities. Collectively, we find that this field has the necessary research tools to discover the pathophysiology of orthopedic implant‐associated biofilm development and maturation, perform clinically relevant studies in animal models, and elucidate mechanisms that allow opportunistic infections in compromised tissues and patients with other health issues.
Midlife to Late‐Life Changes in Plasma Biomarkers of Alzheimer's Disease Pathology and Neurodegeneration and Associations with 5‐Year Cognitive Change in Late‐Life: The Atherosclerosis Risk in Communities (ARIC) Study
Palta, P., Lu, Y, Walker, Keenan A., Sullivan, Kevin, Windham, Gwen Gwen, Thyagarajan, Bharat, Mielke, Michelle M, Hughes, Timothy M., Knopman, David S., Sharrett, A. Richey, Gottesman, Rebecca F., Mosley, Thomas H., Coresh, Josef, Pike, James Russell , Walker, Keenan A. , Thyagarajan, Bharat , Lutsey, Pamela L. , Hughes, Timothy M. , Knopman, David S. , Sharrett, A. Richey, Gottesman, Rebecca F. , Mosley, Thomas H.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106168 Get It

Abstract Background Plasma biomarkers of Alzheimer's disease (AD) pathology and neurodegeneration provide a non‐invasive method to assess brain pathology associated with dementia and cognitive decline. However, it remains unclear whether these biomarkers are differentially associated with changes in specific cognitive domains or how they relate to subsequent cognitive change in participants with or without cognitive impairment. Methods Plasma biomarkers were assayed in a subset of ARIC participants using Quanterix SiMoA technology on stored specimens collected in midlife (visit 3: 1993‐95, mean age: 59) and late‐life (visit 5: 2011‐13, mean age: 77). Biomarkers included amyloid‐β 42 to amyloid‐β 40 (Aβ42:Aβ40) ratio, phosphorylated tau at threonine 181 ( p ‐Tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). Factor scores for global cognition and cognitive domains (memory, language, executive function) were calculated from ten neuropsychological tests administered at visits 5 (2011‐13), 6 (2016‐17), 7 (2018‐19), 8 (2020), and 9 (2021‐22). Linear mixed effects models with multiple imputation of pre‐death cognitive change estimated the association between biomarkers in midlife and late‐life, and biomarker change from midlife to late‐life, with 5‐year change in late‐life global and domain‐specific cognition, adjusting for demographics, lifestyle and cardiovascular risk factors, and APOE‐ε4 status. Exploratory analyses examined effect modification of the biomarker‐global cognition associations by visit 5 adjudicated cognitive impairment. Results Among 1515 participants with plasma biomarkers (60.7% female, 25.5% identified as Black), 39% had late‐life cognitive impairment (Table 1). Higher midlife NfL and GFAP were associated with faster 5‐year declines in global cognition and language during late‐life (Table 2). Only midlife NfL was associated with faster late‐life memory decline. No midlife biomarkers were associated with executive function. In late‐life, lower Aβ42:Aβ40 and higher p ‐Tau 181, NfL, and GFAP were associated with faster declines in global cognition, memory, and language. Midlife to late‐life changes in p ‐Tau 181, NfL, and GFAP were associated with declines in global cognition and language. No consistent effect modification by cognitive impairment was observed (Figure 1). Conclusions Plasma biomarkers of AD pathology, neuronal injury, and astrogliosis, measured at different life epochs (midlife vs. late‐life) show distinct association patterns with subsequent changes in cognitive function across domains.
Extraction of Treatments and Responses From Non–Small Cell Lung Cancer Clinical Notes Using Natural Language Processing
Sivarajkumar, Sonish , Edupuganti, Subhash , Lazris, David , Bhattacharya, Manisha, Davis, Michael K , Dressman, Devin, Thomas, Roby , Hu, Yan , Ren, Yang , Xu, Hua, Yang, P., Huang, Yufei , Wang, Yanshan, Wang, Yanshan , Davis, Michael , Xu, Hua , Yang, Ping , Wang, Yanshan

Mayo Clinic

JCO Clinical Cancer Informatics | January 8, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1200/cci-25-00138 | PMID 41505664 Get It

PURPOSE Manual extraction of treatment outcomes from unstructured oncology clinical notes is a significant challenge for real-world evidence (RWE) generation. This study aimed to develop and evaluate a robust natural language processing (NLP) system to automatically extract cancer treatments and their associated RECIST-based response categories (complete response, partial response, stable disease, and progressive disease) from non–small cell lung cancer (NSCLC) clinical notes. METHODS This retrospective NLP development and validation study used a corpus of 250 NSCLC oncology notes from University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, annotated by physician experts. An end-to-end NLP pipeline was designed, integrating a rule-based module for entity extraction (treatments and responses) and a machine learning module using biomedical clinical bidirectional encoder representations from transformers for relation classification. The system's performance was evaluated on a held-out test set, with partial external validation for relation extraction on a Mayo Clinic data set. RESULTS The NLP system achieved high overall accuracy. On the UPMC test set (64 notes), the relation classification model attained an area under the receiver operating characteristic curve of 0.94 and an F1 score of 0.92 for linking treatments with documented responses. The rule-based entity extraction demonstrated a macro-averaged F1 score of 0.87 (precision 0.98, recall 0.81). Although precision was high for chemotherapy and most response types (1.00), recall for cancer surgery was 0.45. External validation at Mayo Clinic showed moderate relation extraction F1 scores (range: 0.51-0.64). CONCLUSION The proposed NLP system can reliably extract structured treatment and response information from unstructured NSCLC oncology notes with high accuracy. This automated approach can assist in abstracting critical cancer treatment outcomes from clinical narrative text, thereby streamlining real-world data analysis and supporting the generation of RWE in oncology.